ABSTRACT Background. A consensus for which patients with thin melanomas (B1 mm) should undergo sentinel lymph node biopsy (SLNB) is not established. We describe a large single institution experience with SLNB for thin melanomas to determine factors predictive of nodal metastases. Methods. Retrospective review from 2005 to 2010 identified 271 patients with thin melanomas who underwent SLNB, along with 13 additional patients not treated with SLNB who developed a nodal recurrence as first site of recurrence. Clinicopathologic characteristics were correlated with nodal status and outcome. Results. Median age was 55 years, and 53 % of patients were male. Median Breslow thickness was 0.85 mm. Overall, a positive sentinel lymph node (SLN) was found in 22 (8.1 %) of 271 cases; 8.4 % of melanomas C0.76 mm were SLN positive with 5 % of T1a melanomas C0.76 mm and 13 % of T1b melanomas C0.76 mm having SLN metastases. Only two of 33 highly selected patients with melanomas \0.76 mm (both T1b) had a positive SLN. Logistic regression analysis demonstrated that mitotic rate C1/mm 2 significantly correlated with nodal disease (p \ 0.05) and ulceration correlated with SLN metastases (p \ 0.05). Median follow-up was 2.1 years. Overall survival did not differ between positive and negative SLN patients (p = 0.53) but was worse for patients presenting with a nodal recurrence (p \ 0.01).
The incidence of melanoma is increasing with 70 % of new cases diagnosed as thin melanomas (B1 mm). [1] [2] [3] The prognosis for patients with thin melanoma is relatively good, with reported 10-year survival rates of 90 % or greater in most series. 3, 4 However, a subset of patients with thin melanoma experience recurrent disease and melanoma-related mortality. [2] [3] [4] [5] Recurrences at any site occur in close to 10 % of thin melanomas with 3.7-5.2 % of patients developing regional recurrences. [5] [6] [7] Notably, it is not unusual for recurrences to occur more than 10 years after excision of a thin primary. 2, [5] [6] [7] The American Joint Committee on Cancer (AJCC) released the seventh edition staging system for melanoma in 2009. 4, [8] [9] [10] A notable change included the addition of mitotic rate (MR) as a predictor of survival for patients with thin melanoma. 4, 8, 9 However, MR as a predictor of nodal metastases was not addressed in the report. Sentinel lymph node biopsy (SLNB) has emerged as a powerful tool for assessing regional basins for occult nodal metastases. 11, 12 SLNB is recommended by the AJCC Melanoma Staging Committee for melanomas C1 mm in patients with no clinical evidence of metastasis. 4 However, the utility of SLNB for thin melanomas is debated. 13, 14 Arguments against SLNB include that thin melanomas have a low rate of nodal metastases, and the benefit of SLNB in this population is not established. 14 Others argue that there is a subset of patients with thin melanomas who will develop clinically evident nodal disease and thus may benefit from SLNB. 14 Of note, Puleo et al. 6 reported that a positive sentinel lymph node (SLN) was detected in 4.9 % of patients with thin melanomas.
Although no consensus exists regarding which subset of patients with thin melanomas are at greatest risk for nodal metastases, multiple predictive factors have been reported. However, none of these has been validated, and there is little agreement in the literature. 6, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] At Moffitt Cancer Center, our philosophy has been that SLNB is potentially indicated if (a) the yield of a positive SLN is C5 %; (b) the regional failure rate in SLN negative basins is very low relative to the yield of positive SLN; and (c) if nodal status has prognostic and therapeutic impact. This philosophy led us to routinely employ SLNB for otherwise healthy patients with melanomas C0.76 mm but only very selectively in patients with melanomas \0.76 mm. We reviewed our experience with SLNB for thin melanomas to evaluate tumor characteristics predictive of nodal metastases and assess the prognostic value of SLNB in patients with thin melanomas, in hopes of determining the validity of our criteria for selecting thin melanoma patients for SLNB.
METHODS
After obtaining Institutional Review Board approval, a retrospective review was conducted involving patients referred to Moffitt Cancer Center between 2005 and 2010 with thin melanomas, defined as primary tumor thickness of B1 mm. Inclusion criteria were patients who had a SLNB or patients who did not have a SLNB at the time of primary excision but later developed a nodal recurrence (NR) as first site of recurrence. Demographic, clinical, primary tumor pathology, nodal status and outcome data were reviewed.
At Moffitt, SLNB is routinely performed for melanomas C0.76 mm and very selectively for thinner lesions based on findings of poor prognostic features (e.g. ulceration, extensive deep biopsy margin involvement, visible residual tumor present). MR C1/mm 2 was not, absent other factors, considered sufficient to routinely recommend SLNB for melanomas \0.76 mm. SLNB was performed according to techniques previously described. 31, 32 Primary tumors were resected with a 1 cm margin. Patients with SLN metastases were offered completion lymph node dissection (CLND) but encouraged to enroll in the Multicenter Selective Lymphadenectomy Trial (MSLT) II, where participants are randomized to either immediate CLND or ultrasound surveillance of the affected nodal basin.
All cases were reviewed by a Moffitt dermatopathologist. Primary tumor characteristics were assessed, and evaluation of lymph nodes obtained through SLNB consisted of serial sectioning and review of hematoxylin and eosin-stained sections and S-100 and Melan-A immunohistochemistry. Evaluation of CLND specimens consisted of evaluation of lymph nodes \3 mm in diameter in their entirety, and a representative section through the largest diameter area of larger lymph nodes, review of H and Estained sections, and S-100/Melan-A immunohistochemistry as needed.
Usual summary descriptive statistics, i.e., frequency and percentage for discrete variables and mean (standard deviation) and median (range), were provided for baseline demographics, disease characteristics, and outcome variables of interest. Both point estimates and their 95 % confidence intervals (CIs) were reported, whenever appropriate. When exploring an association of a continuous variable with an outcome variable, e.g. nodal status, both its continuous version and a discrete version using an established cutpoint or its median to divide patients into groups were considered. The Wilcoxon Rank-Sum test was used to compare age and Breslow thickness between patients of different outcomes, e.g. between patients with a positive and a negative SLN. v 2 and Fisher's exact tests were employed to study the association of nodal status with various categorical baseline demographics and disease characteristic variables. Simple logistic regression modeling was conducted to determine whether a demographic, disease or clinical variable was a significant predictor for nodal status. Multiple logistic regression with the stepwise variable selection technique was adopted to select the most significant risk factors from a set of predefined potential risk factors, with the level of entry set at 0.10 and the level of stay set at 0.05. Odds ratios (OR) and 95 % CIs were calculated for the odds of having a positive node and/or developing a regional recurrence. The Kaplan-Meier product-limit method was utilized to analyze overall survival (OS) and recurrence-free survival (RFS). The log-rank test was used to test for differences in OS and RFS between any two groups of interest. A p-value of B0.05 was considered statistically significant. All statistical analyses were performed by SAS 9.2 or higher (SAS, Cary, NC).
RESULTS

Patients
A total of 284 patients were included in the study (Fig. 1) . SLNB was performed in 271 patients, while 13 patients did not have a SLNB but developed a NR as first site of recurrence. A positive SLN was seen in 22 (8.1 %) of 271 patients undergoing SLNB. CLND was performed in 15 of the 22 positive SLN cases with no additional tumor-involved nodes found in any patient. Six patients with a positive SLN who did not undergo CLND were randomized to the observation arm of MSLT-II, while one patient was lost to follow-up.
SLNB was negative in 249 cases; however, two patients later developed regional recurrences (false-negative SLNB) leaving 247 patients who had no evidence of nodal disease at last follow-up and were designated as node-negative. To determine the association of primary tumor characteristics with nodal status, all patients with nodal metastases were analyzed. This node-positive group included 22 positive SLNB patients, 13 NR patients, and two false-negative SLNB patients for a total of 37 patients.
The overall median age was 55 years (range 12-84 years), and the majority of patients in both the nodepositive and node-negative groups were male (56.8 % and 52.6 %, respectively). Patient demographics and histopathologic characteristics are shown in Table 1 .
Primary Tumor Characteristics Correlated with Nodal Status
Primary tumor characteristics were correlated with nodal status (Table 1) . Overall median Breslow thickness was 0.85 mm (range 0.3-1 mm) with no significant difference between node-positive and node-negative patients. MR was C1/mm 2 in 21 node-positive patients (63.6 %) and 95 node-negative patients (40.3 %). Ulceration was seen in 14.3 % of node-positive and 5.1 % of node-negative patients. Univariate analysis demonstrated that ulceration (OR 3.11, 95 % CI 1.02-9.45; p = 0.05) and MR C1/mm 2 (OR 2.60, 95 % CI 1.22-5.53; p = 0.01) were significant predictors of nodal metastasis. Multiple regression analysis showed that MR C1/mm 2 was the only significant predictor for nodal metastasis (OR 2.45, 95 % CI 1.14-5.25; p = 0.02), while ulceration trended toward significance (OR 3.09, 95 % CI 0.98-9.77; p = 0.06). Clark level IV/V, regression, vertical growth phase and brisk, nonbrisk, and absent tumor-infiltrating lymphocytes (TIL) did not differ significantly between the two groups, and there were no cases with lymphovascular invasion in either the node-positive or node-negative groups.
Recurrence-free Survival
First site of recurrences are shown in Table 2 . Overall, 3.3 % of SLNB patients experienced recurrences, with 13.6 % of positive SLNB patients but only 2.4 % of negative SLNB patients developing a recurrence. Local recurrences were rare and seen in only 0.7 % (two of 271) of all SLNB patients. Two patients (0.8 %) in the negative SLNB group developed regional recurrences, for a negative predictive value of 99.2 % and a false-negative rate of 8.3 % (two positive nodes missed out of 24 total). One of the false-negative SLNB patients had an ulcerated 0.97 mm melanoma, while the second had a 0.87 mm melanoma with MR 1/mm 2 . Distant recurrences as first site of recurrence were seen in 1.5 % (4 of 271) of SLNB patients, occurring in 9.1 % (2 of 22) of positive but only 0.8 % (2 of 249) of negative SLNB patients. Of note, no recurrences have occurred as of the last follow-up in the six positive SLN patients being observed on MSLT-II.
RFS curves for the negative SLNB, positive SLNB and NR groups are shown in Fig. 2 . RFS was significantly worse for the NR group compared with the negative and positive SLNB groups (both p \ 0.01). A trend toward worse RFS was seen for positive SLNB patients when compared with negative SLNB patients (p = 0.19).
Overall Survival
In total, there were eight deaths after a median follow-up of 2.1 years. Four deaths occurred in the SLNB cohort (1.5 %): one positive SLNB patient (4.5 %) died of metastatic melanoma, while three SLNB-negative patients (1.2 %) died of pancreatic carcinoma, renal cell carcinoma, and an unknown cause, respectively. Four deaths were seen in the NR group, with three of these deaths being melanoma-related and one death with an unknown cause. OS data are shown in Table 2 .
OS curves for the negative SLNB, positive SLNB and NR groups are shown in Fig. 3 for the NR group compared with the negative SLNB group (p \ 0.01) but only a trend was seen when compared with the positive SLNB group (p = 0.10). There was no significant difference in OS between positive and negative SLNB patients (p = 0.53).
Predictors of Sentinel Lymph Node Metastases
Clinicopathologic characteristics were evaluated and correlated with SLN metastasis (Table 3) . A total of 238 melanomas (88 %) were C0.76 mm, while only 33 (12 %) were \0.76 mm. Twenty (91 %) of 22 positive SLNB cases were in melanomas C0.76 mm. A positive SLN was seen in 8.4 % of melanomas C0.76 mm and in 6.1 % of melanomas \0.76 mm; this difference was not statistically significant.
Primary tumor ulceration was seen in 17 patients (6.6 %) who had a SLNB, with a positive SLN in 4 (23.5 %) of 17. In contrast, only 16 (6.6 %) of 241 nonulcerated melanomas had a positive SLN. A positive SLN was seen in 11.9 % of cases with a MR C1/mm 2 vs. only 4.7 % of cases with a MR \1/mm 2 . Nine percent of Clark level IV/V melanomas had a positive SLNB versus 6.8 % of Clark level BIII melanomas. The positive SLNB rate in tumors with and without regression was 7.7 %. The positive SLNB rates were similar in vertical (8.0 %) and radial (7.9 %) growth phase melanomas and in melanomas with (8.3 %) and without (8.2 %) a positive deep biopsy margin. Recurrence-free survival plot with number of subjects at risk positive SLNB was seen in 12.5 % of T1b melanomas C0.76 mm. Two of 11 T1b melanomas \0.76 mm (18.2 %) had SLN metastases; both of these cases had mitotically active tumors with one case having a 0.6 mm nonulcerated melanoma with a MR of 3/mm 2 and the second having a 0.7 mm nonulcerated melanoma with a MR of 1/mm 2 .
DISCUSSION
No consensus exists as to which patients with thin melanomas are at risk for nodal metastases, with numerous studies evaluating predictive risk factors for nodal disease in thin melanomas, including Breslow thickness, Clark level, ulceration, MR, regression, growth phase and TIL. 6, 7, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Several studies have found that a higher MR is associated with nodal metastases in thin melanomas. differ from Kesmodel et al. because MR only trended toward significance as a predictor of SLN metastases in our study. We also utilized a slightly different MR threshold, defining MR by the current AJCC definition of C1/mm 2 . Ulceration was a significant predictor of SLN metastases in our study. Yonick et al. also showed in their study of SLNB in 147 thin melanoma patients that ulceration was an independent predictor of SLN disease (p = 0.047), although most studies have not shown ulceration to be a significant predictor of SLN metastases in thin melanomas. 15, 16, 18, 19, 21, [23] [24] [25] However, because ulceration is uncommon in thin melanomas (4-9 %), ulcerated cases may not have occurred with sufficient frequency to be adequately assessed in these studies.
14 Alternatively, local trauma may have resulted in misclassification of some low-risk tumors as ulcerated, further diluting the limited statistical power to see a difference, especially in multiinstitution studies without central pathology review. 33 Breslow thickness of C0.76 mm is associated with a 4.9-12.8 % rate of SLN metastases, while only 0-2.3 % of melanomas \0.76 mm are associated with SLN disease. 7, 15, 16, 18, 23, 29 Our results are similar to these previously published studies because the risk for SLN metastases was proportional to tumor thickness, with 6.1 % of melanomas \0.76 mm and 8.4 % of melanomas C0.76 mm having a positive SLN. Furthermore, the vast majority (91 %) of patients with a positive SLN in the current study had melanomas C0.76 mm. When we analyzed T classification as stratified by thickness, SLN metastases were seen in approximately 5 % of T1a melanomas C0.76 mm and 13 % of T1b melanomas C0.76 mm. SLNB does not appear to be indicated for T1a melanomas \0.76 mm because none of our cases had SLN metastases. SLN metastases were seen in T1b tumors \0.76 mm. However, in this study the \0.76 mm group represents highly selected patients (only 33 cases out of many hundreds of very thin melanomas seen during that time interval with only 11 T1b) and still we only found two node-positive cases.
Considering the low false-negative and complication rates of SLNB, we believe that using a 5 % risk of nodal metastasis as a threshold for performing SLNB is reasonable.
11,34 Using a 5 % risk threshold, our results suggest that melanoma patients whose tumors are C0.76 mm thick should be considered for SLNB because SLN metastases were seen in 8.4 % of all thin melanomas C0.76 mm and specifically in 5 % of T1a melanomas C0.76 mm and 13 % of T1b melanomas C0.76 mm. However, further study is needed to determine which patients with melanomas \0.76 mm, if any, should be offered SLNB.
A key part of the decision-making process in offering a staging test like SLNB, however, is its ability to predict relapse and survival. In our study, negative SLNB patients had the best RFS and OS, while patients with a nodal relapse fared worst. However, we were unable to demonstrate that a positive SLN had an impact on OS and only saw a trend toward decreased RFS for positive SLNB patients. The median follow-up in our study was relatively short, at just over 2 years, and we saw a number of deaths from causes other than melanoma. Wright et al. demonstrated that for patients with thin melanoma, melanomaspecific survival differences between positive and negative SLNB patients were not seen until after approximately 5 years. 19 We will need to follow our thin melanoma patients and allow our data to mature further before any definitive conclusions about survival can be made. It is worth noting that distant metastasis as a first site of relapse was much more common in our positive SLNB patients, adding credence to the possibility that melanoma-specific survival differences may emerge with extended follow-up.
In summary, thin melanomas have a significant risk for SLN metastases (8.1 % in our series). MR and ulceration both influence nodal status, but how best to use them in selecting patients for SLNB remains unclear. Using a 5 % risk for nodal metastases as a threshold, SLNB should be considered for all melanomas C0.76 mm because SLN metastases were seen in 8.4 % of all melanomas C0.76 mm. Importantly, our population was not preselected for ulceration, MR, growth phase, or other high-risk factors. For surgeons (or patients) who would utilize a 10 % threshold before recommending SLNB, our data would suggest choosing T1b melanomas C0.76 mm (13 % node-positive in our series). The benefits of detecting a positive SLN in patients with thin melanomas include treatment of regional nodal basins at an occult stage, which may improve OS and decrease morbidity when compared with patients who develop a macroscopic NR. 26 Furthermore, detection of a positive SLN also allows for evaluation for systemic therapy or inclusion in clinical trials at an earlier stage.
